Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
European Journal of Pediatrics

Open Access 27-09-2024 | Respiratory Syncytial Virus Infection | RESEARCH

Postpandemic fluctuations of regional respiratory syncytial virus hospitalization epidemiology: potential impact on an immunization program in Switzerland

Authors: Klara Fischli, Nina Schöbi, Andrea Duppenthaler, Carmen Casaulta, Thomas Riedel, Matthias V. Kopp, Philipp K. A. Agyeman, Christoph Aebi

Published in: European Journal of Pediatrics

Login to get access

Abstract

RSV hospitalization epidemiology is subject to rapid changes brought about by the COVID-19 pandemic and the prospect of vaccine prevention. The purpose of this report is to characterize recent epidemiologic and clinical fluctuations and to analyze their potential impact on an immunization program with nirsevimab. This is a 2018–2024 retrospective analysis of all hospitalizations caused by RSV in patients below 16 years of age occurring at an academic Children’s Hospital that serves a defined population. We simulated the vaccine impact against RSV hospitalization by applying the expected effects of the infant immunization program with nirsevimab proposed in Switzerland to observed case counts. We analyzed 1339 hospitalizations. The consecutive occurrence of two major epidemics in 2022–2023 and 2023–2024 had never been recorded previously. The 2023–2024 season witnessed a major shift to older age. Only 61% of patients were below 12 months of age, while prepandemic long-term surveillance since 1997 found a range between 64 and 85% (median, 73%). Age below 3 months, prematurity, airway anomalies, congenital heart disease, and neuromuscular disorders were independently associated with ICU admission. Simulation of the vaccine impact using two scenarios of coverage and efficacy (scenario 1, 50% and 62%, respectively; scenario 2, 90% and 90%) and three different age distributions resulted in an infant vaccine impact of 31.0% (scenario 1) and 81.0% (scenario 2), respectively. Vaccine impact for all patients below 16 years ranged from 22.7 to 24.9% (scenario 1) and 54.2 to 68.8% (scenario 2).
Conclusion: RSV hospitalization epidemiology was characterized by substantial variability in patient age on admission. As the proposed RSV immunization program primarily targets infants, year-to-year fluctuation of cases among older children will cause a variability of vaccine impact of approximately 15%. This information may be useful for physicians and hospital administrators when they anticipate the resources needed during the winter season.
What is Known:
• RSV hospitalization epidemiology was subject to massive disturbances during the COVID-19 pandemic.
• Extended half-life monoclonal antibodies and active maternal immunization offer new means of passive protection of infants against severe RSV disease.
What is New:
• We demonstrate substantial year-to-year fluctuation of the age distribution at the time of RSV hospitalization.
• Up to 40% of annual RSV hospitalizations in a given season occur in children above 12 months of age who do not benefit from maternal RSV immunization and may not be eligible for receipt of a monoclonal antibody.
Appendix
Available only for authorised users
Literature
1.
Collaborators GBDLRI (2018) Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 18(11):1191–210CrossRef
2.
Berbers G, Mollema L, van der Klis F, den Hartog G, Schepp R (2021) Antibody responses to respiratory syncytial virus: a cross-sectional serosurveillance study in the Dutch population focusing on infants younger than 2 years. J Infect Dis 224(2):269–278PubMedCrossRef
3.
Reeves RM, van Wijhe M, Tong S et al (2020) Respiratory syncytial virus-associated hospital admissions in children younger than 5 years in 7 European countries using routinely collected datasets. J Infect Dis 222(Suppl 7):S599–S605PubMedCrossRef
4.
5.
Caserta MT, O’Leary ST, Munoz FM, Ralston SL (2023) Committee on infectious D. palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 152(1):e2023061803PubMedCrossRef
6.
Swenson PD, Kaplan MH (1986) Rapid detection of respiratory syncytial virus in nasopharyngeal aspirates by a commercial enzyme immunoassay. J Clin Microbiol 23(3):485–488PubMedCrossRefPubMedCentral
7.
Wang L, Berger N, Davis PB, Kaelber DC, Volkow N, Xu R (2023) Time trend and seasonality in medically attended respiratory syncytial virus (RSV) infections in US children aged 0–5 years, January 2010-January 2023. Fam Med Community Health 11(4):e002453PubMedCrossRefPubMedCentral
8.
Minney-Smith CA, Foley DA, Sikazwe CT, Levy A, Smith DW (2023) The seasonality of respiratory syncytial virus in Western Australia prior to implementation of SARS-CoV-2 non-pharmaceutical interventions. Influenza Other Respir Viruses 17(3):e13117PubMedCrossRefPubMedCentral
9.
Duppenthaler A, Gorgievski-Hrisoho M, Frey U, Aebi C (2003) Two-year periodicity of respiratory syncytial virus epidemics in Switzerland. Infection 31(2):75–80PubMedCrossRef
10.
Berger TM, Aebi C, Duppenthaler A, Stocker M, Swiss Pediatric Surveillance U (2009) Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001–2005). Infection 37(2):109–16PubMedCrossRef
11.
Sadeghi CD, Aebi C, Gorgievski-Hrisoho M, Muhlemann K, Barbani MT (2011) Twelve years’ detection of respiratory viruses by immunofluorescence in hospitalised children: impact of the introduction of a new respiratory picornavirus assay. BMC Infect Dis 11:41PubMedCrossRefPubMedCentral
12.
Hernandez-Rivas L, Pedraz T, Calvo C, San Juan I, Mellado MF, Robustillo A (2023) Respiratory syncytial virus outbreak during the COVID-19 pandemic. How has it changed? Enferm Infecc Microbiol Clin 41(6):352–5PubMedCrossRef
13.
von Hammerstein AL, Aebi C, Barbey F et al (2021) Interseasonal RSV infections in Switzerland - rapid establishment of a clinician-led national reporting system (RSV EpiCH). Swiss Med Wkly 151:w30057CrossRef
14.
Saravanos GL, Hu N, Homaira N et al (2022) RSV epidemiology in Australia before and during COVID-19. Pediatrics 149(2):e2021053537PubMedCrossRef
15.
Foley DA, Yeoh DK, Minney-Smith CA et al (2021) The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. Clin Infect Dis 73(9):e2829–e2830PubMedCrossRef
16.
Cai W, Kondgen S, Tolksdorf K et al (2024) Atypical age distribution and high disease severity in children with RSV infections during two irregular epidemic seasons throughout the COVID-19 pandemic, Germany, 2021 to 2023. Euro Surveill 29(13):2300465PubMedCrossRefPubMedCentral
17.
Hamid S, Winn A, Parikh R et al (2023) Seasonality of respiratory syncytial virus - United States, 2017–2023. MMWR Morb Mortal Wkly Rep 72(14):355–361PubMedCrossRefPubMedCentral
18.
Hammitt LL, Dagan R, Yuan Y et al (2022) Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 386(9):837–846PubMedCrossRef
19.
Kampmann B, Radley D, Munjal I (2023) Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. Reply N Engl J Med 389(11):1053–1055PubMed
20.
Martinon-Torres F, Miras-Carballal S, Duran-Parrondo C (2023) Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. Euro Surveill 28(49):2300606PubMedCrossRefPubMedCentral
21.
Jones JM, Fleming-Dutra KE, Prill MM et al (2023) Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the advisory committee on immunization practices - United States, 2023. MMWR Morb Mortal Wkly Rep 72(34):920–925PubMedCrossRefPubMedCentral
22.
Fleming-Dutra KE, Jones JM, Roper LE et al (2023) Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the advisory committee on immunization practices - United States, 2023. MMWR Morb Mortal Wkly Rep 72(41):1115–1122PubMedCrossRefPubMedCentral
23.
24.
Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C (2004) Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child 89(10):961–965PubMedCrossRefPubMedCentral
25.
Barbani MT, Gorgievski-Hrisoho M (2009) Rapid detection of respiratory picornaviruses in nasopharyngeal aspirates by immunofluorescence assay. J Clin Virol 45(3):245–248PubMedCrossRefPubMedCentral
26.
Wyder-Westh C, Duppenthaler A, Gorgievski-Hrisoho M, Aebi C (2003) Evaluation of two rapid detection assays for identification of respiratory syncytial virus in nasopharyngeal secretions of young children. Eur J Clin Microbiol Infect Dis 22(12):774–775PubMedCrossRef
27.
Drysdale SB, Cathie K, Flamein F et al (2023) Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med 389(26):2425–2435PubMedCrossRef
28.
Moline HL, Tannis A, Toepfer AP et al (2024) Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season - new vaccine surveillance network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep 73(9):209–214PubMedCrossRefPubMedCentral
29.
Lopez-Lacort M, Munoz-Quiles C, Mira-Iglesias A et al (2024) Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill 29(6):2400046PubMedCrossRefPubMedCentral
30.
Coma E, Martinez-Marcos M, Hermosilla E et al (2024) Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain). Arch Dis Child 0:883
31.
Bardsley M, Morbey RA, Hughes HE et al (2023) Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study. Lancet Infect Dis 23(1):56–66PubMedCrossRef
32.
Mesle MMI, Sinnathamby M, Mook P et al (2023) Seasonal and inter-seasonal RSV activity in the European region during the COVID-19 pandemic from autumn 2020 to summer 2022. Influenza Other Respir Viruses 17(11):e13219PubMedCrossRefPubMedCentral
33.
Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT (2020) The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Natl Acad Sci U S A 117(48):30547–30553PubMedCrossRefPubMedCentral
34.
Cong B, Koc U, Bandeira T et al (2024) Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis. Lancet Infect Dis 24(4):361–374PubMedCrossRef
35.
Nygaard U, Hartling UB, Nielsen J et al (2023) Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study. Lancet Child Adolesc Health 7(3):171–179PubMedCrossRefPubMedCentral
36.
Lomholt FK, Emborg HD, Norgaard SK et al (2024) Resurgence of respiratory syncytial virus in the summer of 2021 in Denmark-a large out-of-season epidemic affecting older children. Open Forum Infect Dis 11(3):ofae069PubMedCrossRefPubMedCentral
37.
Cantais A, Annino N, Thuiller C et al (2024) First RSV epidemic with nirsevimab. Older children than previous epidemics, even when hospitalized. J Med Virol 96(2):e29483PubMedCrossRef
38.
Rao S, Armistead I, Messacar K et al (2023) Shifting epidemiology and severity of respiratory Syncytial virus in children during the COVID-19 pandemic. JAMA Pediatr 177(7):730–732PubMedCrossRefPubMedCentral
39.
Walker GJ, Foster CSP, Sevendal A et al (2024) Clinical, genomic, and immunological characterization of RSV surge in Sydney, Australia, 2022. Pediatrics 153(2):e2023063667PubMedCrossRef
40.
Petros BA, Milliren CE, Sabeti PC, Ozonoff A (2024) Increased pediatric RSV case counts following the emergence of SARS-CoV-2 are attributable to increased testing. MedRxiv 388:1335
41.
Suss RJ, Simoes EAF (2024) Respiratory syncytial virus hospital-based burden of disease in children younger than 5 years, 2015–2022. JAMA Netw Open 7(4):e247125PubMedCrossRef
42.
Dagan R, Hammitt LL, Seoane Nunez B et al (2024) Infants receiving a single dose of nirsevimab to prevent RSV do not have evidence of enhanced disease in their second RSV season. J Pediatric Infect Dis Soc 13(2):144–147PubMedCrossRefPubMedCentral
43.
Lim SA, Chan M, Hu N et al (2024) Risk factors and clinical prognosis associated with RSV-ALRI intensive care unit admission in children <2 years of age: a multicenter study. Pediatr Infect Dis J 43:511PubMedCrossRef
44.
Pelletier JH, Au AK, Fuhrman D, Clark RSB, Horvat C (2021) Trends in bronchiolitis ICU admissions and ventilation practices: 2010–2019. Pediatrics 147(6):e2020039115
45.
Kieffer A, Beuvelet M, Sardesai A et al (2022) Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model. J Infect Dis 226(Suppl 2):S282–S292PubMedCrossRefPubMedCentral
46.
Chua H, Feng S, Lewnard JA et al (2020) The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology. Epidemiology 31(1):43–64PubMedCrossRefPubMedCentral
Metadata
Title
Postpandemic fluctuations of regional respiratory syncytial virus hospitalization epidemiology: potential impact on an immunization program in Switzerland
Authors
Klara Fischli
Nina Schöbi
Andrea Duppenthaler
Carmen Casaulta
Thomas Riedel
Matthias V. Kopp
Philipp K. A. Agyeman
Christoph Aebi
Publication date
27-09-2024
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Pediatrics
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-024-05785-z